Guba S C, Fink L M, Fonseca V
Department of Medicine, University of Arkansas for Medical Sciences and John L. McClellan Memorial Veterans Hospital, Little Rock 72205, USA.
Am J Med Sci. 1998 Apr;315(4):279-85. doi: 10.1097/00000441-199804000-00011.
Hyperhomocysteinemia has recently been identified as an independent risk factor for arterial and venous occlusive disease. In particular, hyperhomocysteinemia has been associated with premature vascular disease, and may act synergistically with other risk factors. Two young patients with severe premature vascular disease, one venous and one arterial, have significantly elevated homocysteine levels. In addition to appropriate anti-coagulant therapy, these patients receive B6 and folate vitamin therapy which normalizes the homocysteine levels. While this course of therapy is prudent, no prospective clinical trials have yet demonstrated that reduction of homocysteine levels correlates with a decreased cardiovascular risk.
高同型半胱氨酸血症最近被确认为动脉和静脉闭塞性疾病的一个独立危险因素。特别是，高同型半胱氨酸血症与血管疾病早发有关，并且可能与其他危险因素协同作用。两名患有严重血管疾病早发的年轻患者，一名是静脉疾病，一名是动脉疾病，其同型半胱氨酸水平显著升高。除了适当的抗凝治疗外，这些患者还接受维生素B6和叶酸治疗，这使同型半胱氨酸水平恢复正常。虽然这一治疗过程是谨慎的，但尚无前瞻性临床试验证明降低同型半胱氨酸水平与心血管风险降低相关。
